Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POLMON vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Polmon (polymyxin B) is a cationic polypeptide antibiotic that disrupts bacterial cell membrane integrity by binding to lipopolysaccharides and phospholipids in the outer membrane, increasing permeability and causing cell death.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Treatment of serious infections caused by susceptible Gram-negative bacteria, including Pseudomonas aeruginosa,Topical use for superficial infections,Off-label: Otitis externa, ophthalmic infections, and infections due to multidrug-resistant organisms
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
1-2 mg intravenously every 2-4 hours as needed; maximum 8 mg/day.
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
Terminal elimination half-life is 12-18 hours in healthy adults; prolonged to 24-36 hours in severe hepatic impairment requiring dose adjustment.
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Polymyxin B is not significantly metabolized; elimination is primarily renal via glomerular filtration.
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Renal excretion of unchanged drug accounts for 40-50% of elimination; biliary/fecal excretion accounts for 50-60%.
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
98% bound to albumin and alpha-1-acid glycoprotein.
Approximately 70% bound to plasma proteins, primarily albumin.
0.2-0.3 L/kg, indicating limited extravascular distribution.
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Oral: 60-80%; intramuscular: 85-95%; intravenous: 100%.
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
GFR 30-59 m L/min: reduce dose by 50%; GFR <30 m L/min: use with caution, reduce dose by 75% or extend interval.
No adjustment required as drug is primarily hepatically metabolized.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
0.01-0.02 mg/kg intravenously every 2-4 hours; maximum 0.1 mg/kg/day.
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
Initially 0.5 mg intravenously; titrate cautiously due to increased sensitivity and risk of respiratory depression.
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
Nephrotoxicity and neurotoxicity: Polymyxin B can cause dose-dependent nephrotoxicity and neurotoxicity (including respiratory paralysis), especially in patients with renal impairment or when used with other nephrotoxic/neurotoxic drugs.
None.
Monitor renal function frequently,Avoid concurrent use with other nephrotoxic or neurotoxic agents,Use with caution in patients with renal impairment, myasthenia gravis, or neuromuscular disorders,Neurotoxic reactions (dizziness, ataxia, paresthesia, confusion, respiratory depression)
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to polymyxin B or any component
Hypersensitivity to theophylline or any component of the formulation.
No known food interactions for topical Polmon.
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
Pregnancy category X. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and human case reports. Second/third trimester: Risk of fetal growth restriction, oligohydramnios, and neonatal pulmonary hypertension. Contraindicated in pregnancy.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Contraindicated during breastfeeding. Excreted in human milk; M/P ratio 1.5. Potential for serious adverse reactions in nursing infants, including respiratory depression and hypotension.
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
No safe dose established; contraindicated. Pregnancy increases clearance of the drug by 30-40%, but teratogenicity precludes use. If inadvertent exposure occurs, dose adjustment is not recommended due to risk; immediate discontinuation warranted.
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
Polmon (policresulen) is a topical antiseptic and astringent used for wound healing and mucosal lesions. Avoid concurrent use with other topical agents; assess for allergic reactions. Do not apply to large open wounds or deep ulcers. Monitor for local irritation.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Apply only to affected area as directed.,Avoid contact with eyes and mucous membranes.,Discontinue use if severe irritation or rash occurs.,Keep out of reach of children.,Do not use on deep wounds or infected areas without medical advice.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POLMON vs AEROLATE JR, answered by our medical review team.
POLMON is a Bronchodilator that works by Polmon (polymyxin B) is a cationic polypeptide antibiotic that disrupts bacterial cell membrane integrity by binding to lipopolysaccharides and phospholipids in the outer membrane, increasing permeability and causing cell death.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POLMON and AEROLATE JR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POLMON is: 1-2 mg intravenously every 2-4 hours as needed; maximum 8 mg/day.. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POLMON and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POLMON is classified as Category C. Pregnancy category X. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and human case reports. S. AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.